Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virology. May 12, 2015; 4(2): 78-95
Published online May 12, 2015. doi: 10.5501/wjv.v4.i2.78
Published online May 12, 2015. doi: 10.5501/wjv.v4.i2.78
Therapeutic and prevention strategies against human enterovirus 71 infection
Chee Choy Kok, SEALS Microbiology, Level 4, Campus Centre, Prince of Wales Hospital, Randwick 2031 NSW, Australia
Author contributions: Kok CC solely contributed to this paper.
Conflict-of-interest: Kok CC is an employee of SEALS Microbiology. The author declares that there is no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Chee Choy Kok, PhD, SEALS Microbiology, Level 4, Campus Centre, Prince of Wales Hospital, Barker Street, Randwick 2031 NSW, Australia. cheechoy.kok@sesiahs.health.nsw.gov.au
Telephone: +61-2-93829197 Fax: +61-2-93829180
Received: October 4, 2014
Peer-review started: October 5, 2014
First decision: October 28, 2014
Revised: November 21, 2014
Accepted: February 9, 2015
Article in press: February 11, 2015
Published online: May 12, 2015
Processing time: 208 Days and 1.3 Hours
Peer-review started: October 5, 2014
First decision: October 28, 2014
Revised: November 21, 2014
Accepted: February 9, 2015
Article in press: February 11, 2015
Published online: May 12, 2015
Processing time: 208 Days and 1.3 Hours
Core Tip
Core tip: This review focuses on therapeutic and prevention strategies for the control of human enterovirus 71 infection. Therapeutic strategies highlighted include natural products, synthetic antivirals, immunotherapy, and the use of olignucleotides. Prevention strategies such as surveillance, physical prevention, and vaccine development form the second part of the review.